The recent Imaging Community Exchange (ICE) webinar series presented “OA/US: How this New Hybrid Modality Can Impact Your Patients.” It was approved for 1.0 ARRT Category A CE credit by the AHRA (AHRA Reference: LEC11689; Expiration Date: 6/8/2023). It was sponsored by Seno Medical. Seno Medical is a medical imaging company formed to commercialize a new modality in cancer diagnosis called opto-acoustic imaging. Almost 100 individuals registered for this webinar.
Dr. A. Thomas Stavros, chief medical officer at Seno Medical, provided a 60-minute presentation. Attendees were able to learn how this new PMA approved hybrid modality uses opto-acoustics (lasers) fused with ultrasound (OA/US) to provide patients a better experience providing superiority over ultrasound alone.
Attendees provided feedback via a survey that also asked, “What was your favorite part of the webinar?”
“The presentation of images to back up the discussion of the scientific principles of optoacoustic ultrasound. The use of AI was very helpful to aid in interpretation.” Said William Lytle Jr., a radiologist .
“Excellent presentation by Dr. Tom Stavros. Glad to see new technology and understanding being applied to breast ultrasound, which will help improve patient care,” said Richard Ellis, radiologist.
The webinar included a question-and-answer session. The complete presentation, including the question-and-answer session, is available for on-demand viewing at ICEwebinars.live.
